Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells.

Liu X, Li F, Stubblefield EA, Blanchard B, Richards TL, Larson GA, He Y, Huang Q, Tan AC, Zhang D, Benke TA, Sladek JR, Zahniser NR, Li CY.

Cell Res. 2012 Feb;22(2):321-32. doi: 10.1038/cr.2011.181. Epub 2011 Nov 22.

2.

The lifelong maintenance of mesencephalic dopaminergic neurons by Nurr1 and engrailed.

Alavian KN, Jeddi S, Naghipour SI, Nabili P, Licznerski P, Tierney TS.

J Biomed Sci. 2014 Apr 1;21:27. doi: 10.1186/1423-0127-21-27. Review.

3.
4.

NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.

Decressac M, Volakakis N, Björklund A, Perlmann T.

Nat Rev Neurol. 2013 Nov;9(11):629-36. doi: 10.1038/nrneurol.2013.209. Epub 2013 Oct 15. Review.

PMID:
24126627
5.
6.

Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons.

Kim HJ.

Biochim Biophys Acta. 2011 Jan;1812(1):1-11. doi: 10.1016/j.bbadis.2010.08.006. Epub 2010 Aug 14. Review.

7.

Nurr1-Based Therapies for Parkinson's Disease.

Dong J, Li S, Mo JL, Cai HB, Le WD.

CNS Neurosci Ther. 2016 May;22(5):351-9. doi: 10.1111/cns.12536. Epub 2016 Mar 25. Review.

PMID:
27012974
8.

Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease.

Chen LW, Kuang F, Wei LC, Ding YX, Yung KK, Chan YS.

CNS Neurol Disord Drug Targets. 2011 Jun;10(4):449-58. Review.

PMID:
21495962

Supplemental Content

Support Center